Low dose epcoritamab plus chemotherapy for relapsed lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of a lower dose of the immunotherapy drug epcoritamab with standard chemotherapy (GemOx) for people with a type of lymphoma called DLBCL that has come back or not responded to previous treatment. The goal is to see if this combination can help get the lymphoma under control before a stem cell transplant (using your own cells).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with diffuse large B-cell lymphoma (DLBCL).
- Your lymphoma has come back after treatment or did not respond to at least one prior therapy.
- Your doctor thinks you could benefit from a stem cell transplant using your own cells.
- You are in generally good health (able to be up and about at least half the day; ECOG score 0-2).
- You do not have an active serious infection, other cancer, or end-stage organ failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding epcoritamab (an immune therapy that helps your body fight cancer) to standard chemotherapy followed by a stem cell transplant. It is for people with large B-cell lymphoma that has come back or not responded to initial treatment.
This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
This trial tests a combination of a new immunotherapy drug called epcoritamab with chemotherapy, followed by a stem cell transplant and more epcoritamab, for people whose large B-cell lymphoma has returned after initial treatment. The goal is to see if this approach can help more people achieve remission and stay in remission.
This study tests whether adding epcoritamab, a new immunotherapy drug, to standard chemotherapy (R-CHOP) can help patients with aggressive B-cell lymphomas. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a new drug, epcoritamab, added to a standard chemotherapy regimen (DA-EPOCH-R) for people with aggressive B-cell non-Hodgkin lymphoma that hasn't been treated before or has had only one round of chemo. It aims to see if this combination works better against certain high-risk types of lymphoma.
Hear when a new Relapsed/Refractory Diffuse Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.